Switching off cancer genes

Written on the 13 May 2009

 
PROGEN Pharmaceuticals is making progress in a technology aiming to ‘switch off’ cancerous genes. 
A pre-clinical study found that Progen’s epigenetic technology is able to inhibit tumour-suppressing enzymes. CEO Justus Homburg is excited about the results.
“In epigenetics we try to switch genes to change how that cell behaves, how to stop it being cancerous rather than saying cancer cells are bad and let’s kill them off — it represents a big shift in the paradigm and that’s why epigenetics is so exciting,” explains Homburg.
But drug development is a lengthy process and Homburg predicts it could be another six years before the product PG11144 is fully developed and on the market as the first, second and third phases of trials still need to be carried out.
“Could it be a long term development? Yes, that could very well be the case, but it’s something well worth pursuing because it is a dramatic change,” he says.
Homburg points out the very risky nature of the drug development industry but he believes the technology’s potential is backed up by the data that shows it does have an effect on tumours.
“We think there’s an opportunity out there, but the vast majority of drug developments don’t succeed,” he says.
“We may be only able to target a specific cancer or a specific disease of a specific cancer – there’s a lot to learn but it’s potentially quite groundbreaking.”
Homburg is confident that Progen is in a good financial position and is comfortable with the company’s patent on the technology.
“One of the things to bear in mind is that we’ve been through a lot of corporate turmoil, but we have been able to put an awful lot of that behind ourselves and during that time pursued research in all of our products,” he says.
“These latest findings prove we have the technology, the expertise and the resources to progress our strong product pipeline.”

Latest News

Q & A WITH FACEBOOK GURU ANDY MCKEON AS HE JOINS AUSTRALIAN SOFTWARE COMPANY LIVETILES

HE was creative director at Apple under the legendary Steve Jobs, and is now a senior Facebook executive. In his n...

EAST COAST PROPERTY BOOM BUILDS PROFITS FOR BRICKWORKS

AUSTRALIA'S residential property boom has helped drive a sharp rise in first half earnings for Brickworks (ASX: B...

COLLINS SUPERSIZES IN EUROPE WITH PURCHASE OF 16 KFC RESTAURANTS IN THE NETHERLANDS

COLLINS Foods (ASX:CKF) has stepped up its European expansion through the purchase of 16 KFC restaurants in the Ne...

CSIRO HELPS DEVELOP AUSTRALIAN PHARMA COMPANY FROM $10 MILLION TO $305 MILLION

GOVERNMENT backed scientists have helped multiply the market value of a previously small Australian pharmaceutical...

Related News

RAY OF HOPE FOR SLATER AND GORDON AS LENDERS STEP IN

EMBATTLED law firm Slater and Gordon (ASX: SGH) has announced to the ASX that it has launched confidential discussion...

SPROUTX PROVIDES THE SEED FOR AGTECH STARTUPS

AGTECH innovation fund SproutX has opened applications for its first accelerator round, backed by $10 million from...

GAS PRICES MAY FORCE BRICKWORKS TO TAKE MANUFACTURING OVERSEAS

BRICKWORKS Limited (ASX:BKW) chairman Robert Millner says soaring energy prices may force the company to turn to offs...

CHINA CONTINUES TO COLLECT AUSSIE PROPERTY ASSETS

CHINESE coin continues to dominate Australia's offshore real estate investment market, accounting for almost h...

EVENTS COMING UP

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter